Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic fat accumulation, inflammation, and hepatocellular injury, without significant alcohol consumption. It represents a progression from simple steatosis to inflammatory and fibrotic changes in the liver, with potential to lead to cirrhosis, liver failure, or hepatocellular carcinoma. Experimental models of steatohepatitis are used to investigate pathophysiological mechanisms and evaluate therapeutic interventions targeting lipid metabolism and liver histology.

References:

[1]. Non-Alcoholic Fatty Liver Disease. sciencedirect.

Nonalcoholic Steatohepatitis (1):

Targets:	NF-κB (1) CaMK (1) NO Synthase (1) Keap1-Nrf2 (1) AMPK (1)

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure

HY-N0385

Gomisin J	66280-25-9	99.97%
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.

Name
Email *

	Sorry, but the email address you supplied was invalid.